Shaoxing Jingxin Pharmaceutical is an API manufacturer based in China. It holds 7 active US drug master files and 12 valid CEPs across a filed portfolio of 9 molecules. Its GMP standing is certified by MFDS (Korea) and US FDA. Its most recent recorded inspection, by US FDA, closed on 24 May 2024 as NAI.
NAI means no action indicated, VAI means voluntary action indicated, and OAI means official action indicated.
| Site | FDA FEI |
|---|---|
| Shangyu, China | Not on file |
| China, China | 3006305239 |
| Molecule | Regulators | Docs |
|---|---|---|
| Rosuvastatin | EDQM, US FDA | 5 |
| Levetiracetam | EDQM, US FDA | 3 |
| Simvastatin | EDQM | 3 |
| Rivaroxaban | EDQM, US FDA | 2 |
| Ticagrelor | EDQM, US FDA | 2 |
| Apixaban | US FDA | 1 |
| Brivaracetam | US FDA | 1 |
| Enrofloxacin For Veterinary Use | EDQM | 1 |
| Levofloxacin | EDQM | 1 |
Also appears on these molecule pages
| Regulator | Filings | GMP certificates |
|---|---|---|
| MFDS (Korea) | None | 2 |
| US FDA | None | 1 |
Choose your molecules and target markets. Shaoxing Jingxin Pharmaceutical comes back tiered against every other supplier able to file there.
Start for free